Results 111 to 120 of about 212,526 (280)

Ibrutinib‐induced severe liver injury

Clinical Case Reports, 2017
Key Clinical Message Ibrutinib, an inhibitor of the Bruton's tyrosine kinase of the B‐cell receptor pathway, is an effective therapeutic agent for B‐cell lymphomas. As these drugs are novel, long‐term or rare adverse events are not yet known.
Amara G. Nandikolla, Olga Derman, Deborah Nautsch, Qiang Liu, Hatef Massoumi, Sangeetha Venugopal, Ira Braunschweig, Murali Janakiram   +7 more
doaj   +1 more source

A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response [PDF]

, 2019
The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II study for patients 61-80 years of age with newly diagnosed CD20+ diffuse large B-cell lymphoma and a higher risk profile (International Prognostic Index ...
Anagnostopoulos, Ioannis, Bittner, Aitomi, Denker, Sophy, Frick, Mareike, Hummel, Michael, Kase, Julia, Na, Il-Kang, Schmitt, Clemens A.   +7 more
core   +2 more sources

Patient‐reported health‐related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib–rituximab versus fludarabine–cyclophosphamide–rituximab

British Journal of Haematology, EarlyView.
Summary Front‐Line therapy in CLL: Assessment of Ibrutinib‐containing Regimens (FLAIR) demonstrated improved progression‐free survival for ibrutinib and rituximab (IR) compared with fludarabine, cyclophosphamide and rituximab (FCR) in previously untreated chronic lymphocytic leukaemia (CLL).
David J. Allsup, David A. Cairns, E. Faye Samy, Lelia Duley, Adrian Bloor, Abraham Varghese, David Meads, Bryony Dawkins, Sean Girvan, Dena R. Howard, Anna Hockaday, Julia M. Brown, Sharon Jackson, Natasha Greatorex, Phoebe Templeton, Michael Tupper, David Phillips, Sonam Yaqub, Di Mortimer, David Stones, Piers E. M. Patten, Andrew Rawstron, Peter Hillmen, Talha Munir   +23 more
wiley   +1 more source

Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption

Bone Reports, 2019
Osteoclasts are responsible for bone erosion in osteoporosis and rheumatoid arthritis (RA). Both Btk and Tec kinases have essential functions in osteoclast differentiation.
Yuko Ariza, Masayuki Murata, Yoshiko Ueda, Toshio Yoshizawa   +3 more
doaj   +1 more source

Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre study

British Journal of Haematology, EarlyView.
Renal dysfunction represents a possible underrecognized complication of symptomatic WM; this condition correlates with adverse global and disease‐specific clinical outcomes. Summary The prognostic significance of impaired renal function in Waldenström macroglobulinaemia (WM) remains poorly defined.
Nicolò Danesin, Francesco Autore, Anna Maria Frustaci, Gianmarco Favrin, Emanuele Cencini, Alessandro Noto, Irene Dogliotti, Jacopo Olivieri, Marcello Riva, Isacco Ferrarini, Anna Maria Barbui, Sara Steffanoni, Dario Marino, Benedetta Puccini, Piero Maria Stefani, Rita Rizzi, Michele Merli, Angela Ferrari, Stefano Luminari, Carlo Visco, Livio Trentin, Andrea Visentin, Annarita Conconi, Simone Ferrero, Marzia Varettoni, Alessandra Tedeschi, Luca Laurenti, Francesco Piazza   +27 more
wiley   +1 more source

Identification of pharmacodynamic biomarker hypotheses through literature analysis with IBM Watson.

PLoS ONE, 2019
BackgroundPharmacodynamic biomarkers are becoming increasingly valuable for assessing drug activity and target modulation in clinical trials. However, identifying quality biomarkers is challenging due to the increasing volume and heterogeneity of ...
Sonja Hatz, Scott Spangler, Andrew Bender, Matthew Studham, Philipp Haselmayer, Alix M B Lacoste, Van C Willis, Richard L Martin, Harsha Gurulingappa, Ulrich Betz   +9 more
doaj   +1 more source

Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells [PDF]

, 2015
Background: Roughly 80% of patients with acute myeloid leukaemia have high activity of Bruton's tyrosine-kinase (BTK) in their blast cells compared with normal haemopoietic cells, rendering the cells sensitive to the oral BTK inhibitor ibrutinib in vitro.
Advani, Bendall, Burger, Burnett, Byrd, Chung, Dasmahapatra, de Rooij, de Weers, Dohner, Dos Santos, Dubovsky, Döhner, Fiedler, Fiedler, Gao, Gu, Hahn, Honda, Horwood, Ikeda, Ito, Juliusson, Kim, Koketsu, Kvinlaug, Ma, Matsunaga, Meng, Miettinen, Oellerich, Rushworth, Rushworth, Rushworth, Rushworth, Rushworth, Schmidt, Sivina, Sun, Tai, Tomasson, Wang, Wang, Welch   +43 more
core   +1 more source

A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome

British Journal of Haematology, EarlyView.
Fostamatinib had 46% durable response, with 73% steroid reduction, in this multicentre retrospective study of refractory wAIHA/ES. Hypertension, gastrointestinal (GI) distress and neutropenia occurred in 23%. Only one patient required drug discontinuation and one patient dose reduction.
Jorge N. Ruiz Lopez, Lipei Shao, Debbie Jiang, Lawrence S. Bailey, Thejaswi Bikkani, Aaron Boothby, Donald C. Moore, Irina Murakhovskaya, Caroline I. Piatek, Mauricio Pineda‐Roman, Ping Jin, Jacqueline N. Poston, Moritz Stolla, David F. Stroncek, Krystalyn E. Hudson, James B. Bussel, Sandhya R. Panch   +16 more
wiley   +1 more source

Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate

eLife, 2015
Bruton's tyrosine kinase (Btk), a Tec-family tyrosine kinase, is essential for B-cell function. We present crystallographic and biochemical analyses of Btk, which together reveal molecular details of its autoinhibition and activation.
Qi Wang, Erik M Vogan, Laura M Nocka, Connor E Rosen, Julie A Zorn, Stephen C Harrison, John Kuriyan   +6 more
doaj   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source